Insta
Russia First Nation To Successfully Complete Human Trials Of A Potential COVID-19 Vaccine
Swarajya Staff
Jul 13, 2020, 09:49 AM | Updated 09:48 AM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
In a major positive development in the global fight against COVID-19, Russia has become the first nation to have completed the world's first-ever clinical trial of a potential vaccine candidate on humans, reports Economic Times.
The vaccine has delivered effective results and as per the report the subjects who had been exposed to the medication will soon be discharged on 15 and 20 July. The trials were conducted by Russia's Centre for Clinical Research on Medications at Sechenov University.
Sharing details on the development, chief researcher Elena Smolyarchuk said, "The research has been completed and it proved that the vaccine is safe."
The first stage of the research on the vaccine had involved a group of 18 volunteers, and the second group which was subjected to the vaccine comprised of 20 volunteers. Post-vaccination, these people were to remain in isolation for a span of 28 days.
Meanwhile, it should be noted that the authorities have not spelt out any details on when the vaccine would enter commercial production stage.
As of now, as per the World Health Organisation (WHO), there are at least 21 vaccines which are presently undergoing key trials across the globe.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.